OrphoMed is a clinical-stage biopharmaceutical company based in San Francisco, California focused on developing novel first-in-class dimer therapeutics. The company's pipeline targets gastrointestinal conditions including irritable bowel syndrome with diarrhea and opioid bowel dysfunction. OrphoMed received FDA Fast Track designation for its lead compound ORP-101 and reported positive Phase 2 results in 2022.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account